The incidence of adenocarcinoma of the uterine cervix has increased in recent years, and it currently comprises approximately 10% to 25% of all cervical cancers.
The incidence of adenocarcinoma of the uterine cervix has increased in recent years, and it currently comprises approximately 10% to 25% of all cervical cancers. [1] [2] [3] The detection of early endocervical adenocarcinoma is a critical issue for the management of patients. However, the subtle cytologic and colposcopic features of early endocervical adenocarcinoma and the lack of clearly defined precursor lesions make early detection challenging. 4, 5 High-risk human papillomavirus (HPV) DNA testing combined with Papanicolaou (Pap) smear testing (cotesting) is useful for cervical screening. 6 However, HPV DNA is negative in a minor subset of cervical adenocarcinoma. 7 A Japanese study found that gastric-type mucinous carcinoma (GMC), including minimal deviation adenocarcinoma (MDA), appears in approximately 25% of cervical adenocarcinoma; GMC is a high-risk HPV-negative cancer. 3, 8, 9 Lobular endocervical glandular hyperplasia (LEGH) is a benign hyperplastic lesion of the endocervical glands. 10 Recent studies suggest that LEGH is a high-risk HPV-negative lesion that may be a precursor of some types of adenocarcinoma, including GMC and MDA. 9, [11] [12] [13] [14] [15] [16] The presence of these HPV-negative adenocarcinomas and their precursors can confuse the results of cervical screen cotesting.
LEGH and GMC produce pyloric gland mucin that shows gastric differentiation in these cells. Furthermore, HIK1083 and MUC6, antibodies against pyloric gland mucin, are immunopositive in these lesions. 12, 14, 17, 18 We previously reported that detection of gastric-type mucin in vaginal discharge using the HIK1083-labeled latex agglutination test (HIK1083 latex test) is useful for detecting LEGH and GMC. 15 On a conventional Pap smear, gastric-type mucin shows up as cytoplasmic yellow mucin, while normal endocervical, glandular, cytoplasmic mucin has a pinkish color. 18, 19 Thus, screening for endocervical cells possessing yellow mucin on a Pap smear provides a diagnostic clue for the presence of LEGH and thus the presence of adenocarcinoma associated with LEGH and GMC. In this study, we prospectively evaluated the clinical importance of yellow mucin on conventional Pap smears.
Materials and Methods
We enrolled patients who received cytologic smears at the Department of Obstetrics and Gynecology, Yamanashi University Hospital, Yamanashi, Japan, between January 2000 and December 2016. All Pap smears were prepared by conventional methods. We used the Cytobrush Plus (CooperSurgical, Trumbull, CT) for cervical smears, and the Endocyte endometrial sampler (Laboratoire, Paris, France) or the Softcyte (Soft Medical, Tokyo, Japan) for endometrial smears. All patients provided their informed consent.
When yellow mucin was observed in endocervical cells on a Pap smear, we described it as "atypical endocervical cells with gastric-type mucin" (AEC-GAM) in addition to the original cytologic diagnoses. We also identified the finding as AEC-GAM when endocervical cells with yellow mucin were observed on endometrial smears.
To confirm gastric-type mucin, we used the finding of a "two-color pattern" in the same cytologic smear ❚Image 1❚. All cytotechnologists and pathologists that assessed samples received special training for identifying gastric-type mucin. Two cytotechnologists independently performed cytologic screening on each smear. If their results were discordant, a third cytotechnologist, blinded to the previous assessments, was consulted. We recorded the concurrent judgment of two of these cytotechnologists, and cytopathologists finally confirmed the cytologic assessment of each case.
We performed HIK1083 latex tests on cervical mucus using the HIK1083 Latex Kit (Kanto Chemical, Tokyo, Japan) in all patients whose Pap smear samples contained endocervical cells with yellow mucin. We obtained patients' cervical mucus by cotton swab within 1 month of the Pap smear tests. The latex agglutination test is positive if gastric-type mucin present in a cervical sample is greater than 1 U/mL (mucinous quantity having the antigen activity of 1 mg of p-nitrophenyl-N-acetyl-α-d-glucosaminide). 15, 20 Patients with watery vaginal discharge, multiple cervical cysts on vaginal sonography, endocervical cells with yellow mucin on Pap smear, and positive HIK1083 latex tests received a magnetic resonance imaging (MRI) examination to detect LEGH or malignancy. If patients did not have atypical cytologic findings, they were followed by cytology and vaginal sonography every 3 to 6 months. When cervical cancer was suspected by cytologic and/or imaging examination, we performed histologic examination, including cervical biopsy, endocervical curettage, and cone biopsy. For statistical analyses, we used the Mann-Whitney U test, with P values of less than .05 considered statistically significant.
Results
In this prospective study, 58,752 cervical smear samples and 30,346 endometrial smear samples were collected. There was AEC-GAM in 172 (0.29%) of the 58,752 cervical samples and 78 (0.26%) of the 30,346 endometrial samples, giving a total of 250/89,098 samples (0.28%). In paired samples of cervical and endometrial smears, 112 pairs showed AEC-GAM in the cervical and/or endometrial smear in the following combinations: only in the cervical smear, 36 pairs (32%); only endometrial smear, 28 ❚Image 1❚ Two-color pattern on Papanicolaou smear. Yellow color corresponds to gastric-type mucin (arrows), and pink color is normal endocervical mucin (arrowheads) (Papanicolaou stain, ×20).
pairs (25%); and both smears, 48 pairs (43%). In total, 250 cytologic samples with AEC-GAM were obtained from 74 patients. The rates at which we found AEC-GAM in either or both sample types increased gradually over our study period ❚Figure 1❚.
Of the 74 patients from whom samples with AEC-GAM were obtained, nine sought a second opinion and 65 received additional workup and regular follow-up. Fortyone patients underwent hysterectomy due to the following preoperative diagnoses: cervical adenocarcinoma (six cases), adenocarcinoma in situ (AIS) (six cases), cervical squamous cell carcinoma (SCC) (one case), high-grade squamous intraepithelial lesion (one case), LEGH (22 cases), leiomyoma (three cases), adenomyosis (one case), and prolapses uteri (one case).
Postoperative histologic examination revealed 28 cases of LEGH and 13 cases of pyloric gland metaplasia (PGM) ❚Table 1❚. Among 28 cases of LEGH, endocervical adenocarcinoma was found in eight cases: LEGH and AIS (five cases), LEGH and MDA (one case), LEGH and GMC (one case), and LEGH and usual-type endocervical adenocarcinoma (UEA) (one case) ❚Image 2❚. Five cases of cervical carcinoma were found in the cases of PGM: PGM and AIS (one case), PGM and UEA (three cases), and PGM and SCC (one case).
Histology in five cases of AIS, one case of MDA, and one case of GMC suggested there was transformation from LEGH to AIS/adenocarcinoma. However, in one case of UEA coexisting with LEGH, a relationship between the two lesions was not observed on histology. Some minute lesions of PGM were found in one case of AIS, three cases of UEA, and one case of SCC.
We clinically diagnosed eight patients with LEGH due to watery vaginal discharge, yellow mucin on Pap smear, positive HIK1083 latex tests, and multiple cervical cysts seen on vaginal sonography and MRI. An additional 16 cases were clinically considered to be PGM because they did not show obvious cervical cystic lesions. In these 24 patients, follow-up continues, and endocervical cells with yellow mucin have been continuously observed.
Consequently, of 65 patients with AEC-GAM, 28 patients (43%) and 13 patients (20%) were histologically diagnosed with LEGH and PGM, respectively. We diagnosed a total of 36 patients (55%) with LEGH, including clinically diagnosed LEGH. The rate at which we found AIS/adenocarcinoma associated with LEGH was 25% (7/28) of the LEGH cases, 19% (7/36) when we included clinically diagnosed LEGH, and 11% (7/65) of all cases that had endocervical cells with yellow mucin.
HIK1083 latex tests were positive in 56 (88%) of the 64 patients that had endocervical cells with yellow mucin; the test was not performed in one case of AIS with PGM. Of the patients that underwent hysterectomy, 100%
❚Figure 1❚ The rate of detection of atypical endocervical cells with gastric-type mucin (AEC-GAM) in cytologic specimens. (28/28) of LEGH cases and 67% (eight of 12) of the PGM cases were positive for HIK1083 latex tests. The median patient age was significantly older in cases of AIS/adenocarcinoma associated with LEGH (seven cases, median age 67 years, range 55-79 years) than in cases of LEGH without malignancy (20 cases, median age 54 years, range 37-76 years) (P < .05). The median age at the initial visit was older in cases of PGM (13 cases, median age 63 years, range 33-79 years) than in cases of LEGH (28 cases, median age 59.5 years, range 37-79 years). However, there was no significant difference between the two groups.
We investigated the preoperative cervical smears of 28 cases of LEGH with and without adenocarcinoma ❚Table 2❚. We divided the smears into three types of cell clusters based on cytologic findings. Type 1 cell clusters had a honeycomb appearance or a picket fence configuration of endocervical cells with yellow mucin, bland nuclei, and distinct cell borders; this is considered characteristic findings for LEGH ❚Image 3A❚. Type 2 cell clusters had a three-dimensional appearance with varicolored mucin of pink, yellow, and orange, irregular arrangement of the hyperchromatic nuclei, and occasional conspicuous nucleoli. These were atypical cells but less atypical than the appearance of adenocarcinoma cells ❚Image 3B❚. Type 3 cell clusters were highly crowded clumps of atypical cells with scarce mucin, enlarged hyperchromatic nuclei, and conspicuous nucleoli that we classified as AIS or adenocarcinoma ❚Image 3C❚. We observed type 1 clusters in all cases of LEGH. We found only type 1 clusters in 18 cases for which we gave a cytologic diagnosis of AEC-GAM, low grade (AEC-GAM, LG); these patients had postoperative histologic diagnoses of LEGH. One case had type 1 and type 3 clusters, and the cytologic diagnosis was adenocarcinoma with AEC-GAM, LG. The postoperative diagnosis was UEA combined with LEGH because there was no relationship between the two components.
Two cases had both type 1 and type 2 clusters, and their cytologic diagnoses were AEC-GAM, high grade (AEC-GAM, HG). Histologically, one case revealed no obvious atypical lesions. In the other case, only one large gland had some cellular and structural atypia, and the postoperative diagnosis was atypical LEGH. Seven cases contained all three types of clusters, one of which had type 3 clusters displaying less atypia. We diagnosed that case as AEC-GAM, HG suspicious of adenocarcinoma. Four cases with type 3 clusters displaying a peripheral feathering arrangement also were diagnosed as AIS with AEC-GAM, HG. These five cases with type 3 clusters diagnosed cytologically as AEC-GAM, HG had postoperative diagnoses as AIS associated with LEGH. We diagnosed two cases with type 3 clusters that had higher nuclear and structural atypia as adenocarcinoma with AEC-GAM, HG. One was diagnosed histologically as MDA associated with LEGH, the other as GMC associated with LEGH. All cases of AIS/adenocarcinoma associated with LEGH had overlapping features of the three cluster types.
Discussion
Altered mucin expression has been associated with malignant transformation in various organs such as the pancreas, gallbladder, and stomach. [21] [22] [23] Thus, mucin pattern can be a useful marker to detect cancers and precancerous lesions. In this study, we hypothesized that gastric-type mucin on Pap smears is a surrogate marker for HPV-negative endocervical adenocarcinoma and its precursors.
In the present study, we observed endocervical cells with gastric-type mucin in 0.29% of cervical smear specimens and 0.26% of endometrial specimens. This is the first study to examine the prevalence rate of endocervical cells with gastric-type mucin on Pap smear. The rate of finding AEC-GAM on cytologic smears recently has increased slightly in cervical and endometrial sampling, although this change may have been influenced by the improvement in sampling and diagnostic ability.
It is noteworthy that adenocarcinoma-associated LEGH was detected in 11% of the cases that had endocervical cells with yellow mucin. Furthermore, four of these cases developed AIS as we followed them for LEGH. These results emphasize that screening for endocervical cells with yellow mucin can provide diagnostic value, and, once LEGH is detected, continuous follow-up may be needed to detect early adenocarcinoma. Our results also indicate that LEGH has the potential to transform into cancer.
The samples of adenocarcinoma associated with LEGH in our study exhibited various cytologic forms: endocervical cells contained yellow mucin, varicolored mucin, or scarce mucin, and cell clusters showed a spectrum of nuclear and structural atypia. We regarded endocervical cells with varicolored mucin and irregular nuclear arrangements as AEC-GAM, HG, and those with less atypia and yellow mucin as AEG-GAM, LG. Atypical endocervical cells with varicolored mucin were found in cases of adenocarcinoma associated with LEGH and one case of atypical LEGH, but not in the case of UEA incidentally found with LEGH. We suggest that these cell The present study demonstrated that endocervical cells with gastric-type mucin provides diagnostic value on cervical cytology. Consequently, we propose adding a novel category of AEC-GAM to the category of AEC and further dividing AEC-GAM into either a lowor high-grade depending on the presence of varicolored mucin and nuclear atypia. The Bethesda System for reporting cervical cytology does not include a category of endocervical cells exhibiting gastric differentiation. 24 To correspond to the current Bethesda System in routine practice, it would be appropriate to classify AEC-GAM,
LG as "AEC-not otherwise specified (NOS) with gastric-type mucin (GAM)" and AEC-GAM, HG as "AECfavor neoplastic (FN) with GAM."
According to the 2012 American Society for Colposcopy and Cervical Pathology Consensus Guidelines, colposcopy and endocervical sampling are recommended for women with categories of AEC-NOS and AEC-FN. 25 However, colposcopically directed biopsy will fail to detect LEGH and adenocarcinoma associated with LEGH, because most of these lesions are typically located in the upper portion of the endocervical canal. 14, 26 In addition, LEGH and adenocarcinoma associated with LEGH are high-risk HPV-negative endocervical lesions and it will complicate cotesting. 9, 14 We recommend additional HIK1083 latex test for women with categories of AEC-GAM to confirm gastric-type mucin. MRI examination is also recommended to detect LEGH and adenocarcinoma associated with LEGH, because LEGH show a multicystic pattern. 26 For clinical management of women with the categories of AEC-NOS with GAM or AEC-FN with GAM, pathologists and gynecologists need to recognize the clinicopathologic characteristics of LEGH and adenocarcinoma associated with LEGH.
There are several concerns when attempting to categorize AEC-GAM. First, it is difficult to recognize yellow mucin on liquid-based cytology because the mucin color becomes paler. Second, the cytopathologist and cytotechnologist must be trained to detect the yellow mucin. Third, adequate cervical samplings from throughout the cervical canal are required. LEGH and AIS/adenocarcinoma associated with LEGH are located in the upper portion of the endocervical canal, although HPV-positive UEA usually involves the squamocolumnar junction. 14, 26 In the present study, we obtained endometrial smears to look for yellow mucin.
The prevalence of adenocarcinoma with gastric differentiation will increase relative to HPV-positive adenocarcinoma as a consequence of HPV vaccination programs, and precursor lesions will not be detected by primary HPV-based screening programs. 27 We recommend establishing the novel AEC-GAM category in addition to AEC-NOS and AEC-FN categories for more effective cytologic screening for HPV-negative cervical cancers.
